Abstract: The present invention relates to a method of reducing acne relapse or rosacea relapse rate or severity, by reducing the skin's immunological response, wherein the method comprises administering a topical composition comprising at least one of a PDE4 inhibitor, a JAK inhibitor, an AhR modulator, or any combination thereof.

Abstract: A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.

Abstract: This invention, in some embodiments thereof, relates to regimens, topical compositions comprising ruxolitinib, deuterated ruxolitinib or pharmaceutically acceptable salt thereof and uses thereof for the treatment of inflammatory skin conditions.

Abstract: Provided herein compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichthyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

Abstract: The present invention relates to crystalline polymorphs of Tapinarof, e.g., Tapinarof crystalline Form B, Form C, and Form D, pharmaceutical compositions comprising the same, processes for preparation thereof, and uses thereof for treatment of skin disorders.

Abstract: Provided herein are topical composition comprising tapinarof and combination compositions comprising a therapeutically effective dose of tapinarof and a therapeutically effective dose of at least one additional active agent, selected from at least one corticosteroid, calcipotriene, at least one JAK inhibitor and combinations thereof, and a carrier suitable for topical administration. The above compositions are useful for the treatment, prevention or alleviation of skin disorders selected from psoriasis and atopic dermatitis and exhibit synergistic or additive effects which allow reducing the doses of the active agents in the compositions.

Abstract: The present disclosure, in some embodiments, relates to a low permeable topical composition comprising roflumilast, N-oxide of roflumilast or salts thereof, and to a method of treatment of a skin disorder by topical administration of said composition.

Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

Abstract: A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.

Abstract: Provided herein is a topical combination composition comprising tapinarof, a PDE4 inhibitor and optionally at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above compositions are useful for the treatment, prevention or alleviation of a skin disorder selected from psoriasis, dermatitis, acne, rosacea, ichthyosis, scaling skin, imbalance of skin barrier and tinea and exhibit synergistic and/or additive effects allowing to reduce the active agents amounts in the combination compositions.

Abstract: A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.

Abstract: Provided herein is a topical composition comprising tapinarof and methods of treatment of cutaneous adverse effects caused by oncological therapy with the tapinarof composition. The tapinarof compositions of this invention are useful for the treatment, prevention or amelioration of cutaneous and/or mucosal adverse effect caused by oncological therapy selected from chemotherapy, immunotherapy, radiation therapy, targeted therapy, hormone therapy and stem cell transplant therapy.

Abstract: Provided herein is a topical combination composition comprising tapinarof, an additional AhR activator and optionally further comprising at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above compositions are useful for the treatment, prevention or alleviation of a skin disorder and exhibit synergistic and/or additive effects which allow reducing the amounts of the active agents in the compositions.

Abstract: Provided herein is a topical combination composition and a method of treatment of an inflammatory skin condition by administration of said composition comprising at least one Janus kinase inhibitor (JAK inhibitor) and at least one additional active agent elected from benzoyl peroxide (BPO), at least one retinoid, tapinarof, at least one antibiotic, at least one antiandrogen, at least one acaricide and combinations thereof and a carrier suitable for topical administration. The JAK inhibitor and the at least one additional active agent exhibit an additive or synergistic effect, allowing to reduce the amounts of active agents in the composition.

Abstract: The present invention, in some embodiments thereof, relates to treatment of hidradenitis suppurativa by topical or intralesional administration of a composition comprising tapinarof and optionally at least one additional active agent. The composition of the present invention is useful for the treatment, prevention or amelioration of hidradenitis suppurativa.

Abstract: Provided herein is a topical combination composition comprising a therapeutically effective amount of at least one acaricidal active agent, a therapeutically effective amount of at least one essentially non-acaricidal anti-inflammatory active agent and a carrier suitable for topical administration for the treatment of rosacea. Also provided are combination compositions optionally further comprising a vasoconstrictor.

Abstract: This invention is directed to a regimen administration of combination of minocycline and benzoyl peroxide and uses thereof for treating a skin disorder such as acne or rosacea.

Abstract: Disclosed are topical compositions and methods of treatment of a skin or mucosal disorder selected from palmoplantar psoriasis, hereditary palmoplantar keratoderma, acquired palmoplantar keratoderma, hydradenitis suppurativa, dermatitis, ichthyosis vulgaris, hereditary ichthyosis, acquired ichthyosis, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, Gorlin syndrome, nail psoriasis, flexural/inverse psoriasis, non-melanoma skin cancer, Cutaneous T-cell lymphoma and precancerous skin, mucosal and nail lesions, by once or twice daily topical administration to a subject of a composition comprising therapeutically effective amount of tapinarof.

Abstract: A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.

Abstract: Disclosed are simple yet stable and effective compositions comprising from about 1% to about 5% by weight of the composition of a minocycline or mixtures thereof and pharmaceutically acceptable ingredients comprising from about 60% to about 99% by weight of the composition of at least one hydrophobic oil, and from about 5% to about 25% by weight of the composition of at least one fatty alcohol, wherein the at least one hydrophobic oil and the at least one fatty alcohol are sufficient to ensure the pharmaceutically acceptable assay stability of the minocycline in the composition under 3 months accelerated stability conditions at 40° C./75% RH. Also disclosed are methods of treatment of acne, rosacea and impetigo.